Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2419520 | 0.86 | ADRA2C (0.47) | ADRA2CMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL1267083 | 0.82 | ADRA2C (0.54) | ADRA2CMEN1KMT2AMAPTALDH1A1 | |
| Cyclopropane SCHEMBL3856757 | 0.81 | ADRA2C (0.48) | ADRA2CMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL1267497 | 0.81 | ADRA2C (0.49) | ADRA2CMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL2418833 | 0.81 | ADRA2C (0.47) | ADRA2CMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL3568771 | 0.80 | ADRA2C (0.59) | ADRA2CMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL3865162 | 0.78 | ADRA2C (0.43) | ADRA2CMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL2419948 | 0.74 | ALDH1A1 (0.48) | ADRA2CMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL2422934 | 0.73 | ALDH1A1 (0.49) | ADRA2CMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL2420625 | 0.73 | MAPT (0.51) | ADRA2CMEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017772-B2 | Substituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain | GRUENENTHAL GMBH (DE) | 2011-09-13 | — | — | US | claimed |
| US-20100004252-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND/OR INHIBITION OF PAIN | GRUENENTHAL GMBH (DE) | 2010-01-07 | — | — | US | claimed |
| US-7625900-B2 | Sutstituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain | GRUENENTHAL GMBH (DE) | 2009-12-01 | — | — | US | claimed |
| US-20080167315-A1 | Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in the Treatment and/or Inhibition of Pain | GRUENENTHAL GMBH (DE) | 2008-07-10 | — | — | US | claimed |
| US-8017772-B2 | Substituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain | GRUENENTHAL GMBH (DE) | 2011-09-13 | — | — | US | disclosed |
| US-20100004252-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND/OR INHIBITION OF PAIN | GRUENENTHAL GMBH (DE) | 2010-01-07 | — | — | US | disclosed |
| US-7625900-B2 | Sutstituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain | GRUENENTHAL GMBH (DE) | 2009-12-01 | — | — | US | disclosed |
| US-20080167315-A1 | Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in the Treatment and/or Inhibition of Pain | GRUENENTHAL GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004252-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND/OR INHIBITION OF PAIN | KCNQ2, KCNQ1, KCNJ2 | ADRA2C 272/4885MEN1 3558/4885KMT2A 770/4885 |
| US-20080167315-A1 | Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in the Treatment and/or Inhibition of Pain | KCNQ2, KCNQ1, KCNJ2 | ADRA2C 272/4885MEN1 3558/4885KMT2A 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.